Skip to content


  • Poster presentation
  • Open Access

Adherence in HIV-1 infected children taking once daily HAART with Didanosine + Lamivudine + Efavirenz in West Africa. ANRS 12103 clinical trial

  • 1,
  • 1,
  • 2,
  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 1,
  • 1,
  • 3 and
  • 4
Retrovirology20096 (Suppl 1) :P17

  • Published:


  • Clinical Trial
  • Infectious Disease
  • Cancer Research
  • Time Slot
  • Lamivudine


Assess adherence and determine the reasons of poor adherence in HIV-1 infected children taking once-a-day paediatric HAART with DDI+3TC+EFV in Bobo-Dioulasso, Burkina Faso.


Fifty-two HIV-1 infected children were followed during a 12-month period of the II phase clinical trial. Adherence was assessed using monthly pill counts. A questionnaire was administered quarterly in order to investigate reasons of poor adherence.


During the 12 months of follow up, two children died. Seven became resistant and 118 questionnaires were administered. Only two caregivers declared missed takings the previous week, which was contrasting with the counting. The difficulties reported by the caregivers were related to the time slot, and the instruction to take the pills on an empty stomach, the length of the treatment, the ARV's form and palatability.

The adherence rate was 98% and 32% of the patients had always had an adherence rate ≥ 95%. The adherence was not correlated to the socio-demographic factors and to the immuno-virological response.


Good adherence of this once daily's treatment study. No association between adherence, the socio-demographic factors and the infection's markers.

Authors’ Affiliations

Service de Pédiatrie, CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso
Centre Muraz, Bobo-Dioulasso, Burkina Faso
Laboratoire de bactériologie-Virologie, CHU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France
UMR 145, IRD, Centre de Recherche Cultures Santé Sociétés/IFEHA, Université Paul Cézanne, Aix en Provence, France


© Somé et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.